Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids)
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 15
- Registration Number
- NCT05526521
- Locations
- 🇺🇸
Washington University School of Medicine- Site Number : 8400004, Saint Louis, Missouri, United States
🇺🇸Childrens Hospital Medical Center of Akron- Site Number : 8400020, Akron, Ohio, United States
🇺🇸Cincinnati Children's Hospital Medical Center - PIN- Site Number : 8400001, Cincinnati, Ohio, United States
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2024-10-26
- Target Recruit Count
- 600
- Registration Number
- NCT05436535
- Locations
- 🇺🇸
Children's Hospital Los Angeles: Division of Clinical Immunology & Allergy, Los Angeles, California, United States
🇺🇸University of Pennsylvania, Perelman Center for Advanced Medicine: Department of Dermatology, Philadelphia, Pennsylvania, United States
🇺🇸North Carolina Children's Hospital: Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Chapel Hill, North Carolina, United States
IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 7
- Registration Number
- NCT05372003
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2024-06-28
- Target Recruit Count
- 240
- Registration Number
- NCT05347771
- Locations
- 🇺🇸
Boston Children's Hospital: Department of Immunology, Boston, Massachusetts, United States
🇺🇸Cincinnati Children's Hospital Medical Center: Asthma Center, Cincinnati, Ohio, United States
🇺🇸Children's National Medical Center: Children's Research Institute, Washington, District of Columbia, United States
Real Life Experience Survey of Dupilumab in the Netherlands
- First Posted Date
- 2022-04-18
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Gert-Jan Braunstahl
- Target Recruit Count
- 120
- Registration Number
- NCT05331755
- Locations
- 🇳🇱
Franciscus Gasthuis & Vlietland, Rotterdam, Netherlands
Ethnic Differences in Mechanisms of Action of Dupilumab
- First Posted Date
- 2022-03-07
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 30
- Registration Number
- NCT05268107
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.
- Conditions
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- OptiSkin Medical
- Target Recruit Count
- 15
- Registration Number
- NCT05265234
- Locations
- 🇺🇸
OptiSkin Medical, New York, New York, United States
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 208
- Registration Number
- NCT05263206
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai- Site Number : 8400034, New York, New York, United States
🇯🇵Investigational Site Number : 3920006, Sapporo, Hokkaido, Japan
🇺🇸Kern Allergy and Medical Research- Site Number : 8400016, Bakersfield, California, United States
Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Children's Hospital of Philadelphia
- Target Recruit Count
- 21
- Registration Number
- NCT05247866
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT05203380
- Locations
- 🇺🇸
DermAssociates, LLC, Rockville, Maryland, United States
🇺🇸Clinical Research Center of Alabama, LLC, Birmingham, Alabama, United States
🇺🇸Pediatric Skin Research, LLC, Coral Gables, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.